No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Only a very small proportion of an administered dose of miltefosine is excreted in the unchanged form and there is little potential for an interaction with emtricitabine and tenofovir due to competition for renal elimination pathways.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking